Disruption of HER2–HER3 dimerization is crucial for HER2-driven signalling and is particularly focused proficiently by pertuzumab132. The good benefits from pertuzumab trials supported a strategy of targeting HER3, which has a crucial position in HER2-mediated tumorigenesis. HER3 is exclusive compared with other HER family members as it is actually described https://www.directivepublications.org/journal-of-clinical-breast-cancer/